Showing 34,862 articles by Roger Pebody

Filters Author: Roger Pebody

Roger joined NAM in 2008 as an Editor and became Managing Editor in 2018. He is responsible for co-ordinating the editorial content of aidsmap.com, including news coverage and patient information materials. His involvement in HIV work began at Gay Men Fighting AIDS in the mid-1990s. Twitter: @RogerPebody

Cancer

Delayed Start of HIV Therapy Tied to Small Increase in Risk of AIDS-Related Cancers

Editor's pick
Medscape (requires free registration)
17 March 2021
Weight gain & lipodystrophy

HIV research: Increased weight gain with TAF medication

Editor's pick
EurekAlert
17 March 2021
People & personal stories

Trials, tinsel & tango: Get to know Linda-Gail Bekker's COVID world

Editor's pick
Bhekisisa
17 March 2021

CROI 2021: Long-acting injectables for HIV treatment and prevention, Wednesday 17 March 2021

March 2021
Access to healthcare

‘Resilient’ HIV programmes in African countries have maintained viral suppression during the COVID-19 pandemic

News
17 March 2021
Weight gain & lipodystrophy

What are the roles of TAF and integrase inhibitors in weight gain?

News
16 March 2021
Drug interactions & pharmacokinetics

PrEP does not lower hormone levels in young transgender people, but lower PrEP levels seen in some transgender women

News
16 March 2021
Vaccinations & immunisations

Important COVID risk and vaccine updates

Editor's pick
BHIVA
16 March 2021
Ethnic & cultural minorities

Racial/Ethnic Minorities With HIV More Likely to Get COVID-19 in US

Editor's pick
NATAP
16 March 2021
Coronavirus

In US Groups COVID Testing More Likely With HIV, But Positivity Similar With/Without HIV

Editor's pick
NATAP
16 March 2021
Diabetes

Risk factors for progression from prediabetes to diabetes in persons with HIV

Editor's pick
NATAP
16 March 2021
Treatment simplification strategies

Four-days-on, three-days-off treatment regimen still looks effective after two years

News
16 March 2021
Pregnancy and vertical transmission

Another HIV Tivicay Birth Outcome: Better Infant Survival

Editor's pick
Medscape (requires free registration)
15 March 2021
Injectable & long-acting HIV treatment

Injectable HIV medications must be practical and affordable, conference hears

News
15 March 2021
Finance & funding

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

News
15 March 2021
Transgender people

Gender-affirming surgery associated with sustained viral suppression

News
15 March 2021
Contraception

Doubling the dose of emergency contraception is a safe and effective way of overcoming efavirenz interaction

News
15 March 2021
PrEP science

Interactions between PrEP and gender-affirming hormone therapy A research briefing

About HIV
March 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
Money

The financial cost of living with HIV in Asia

Editor's pick
Avert
15 March 2021
HIV testing programmes & uptake

Healers Lend a Hand to HIV Testing in Rural Uganda

Editor's pick
MedPage Today
15 March 2021
Sexually transmitted infections tests & treatment

Twice-daily oral cefixime nearly 90% successful in treating early syphilis

Editor's pick
Healio
15 March 2021
Conference announcements & declarations

Really Rapid Review — CROI 2021 Virtual

Editor's pick
HIV and ID Observations
15 March 2021
Injectable & long-acting HIV treatment

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years

News
12 March 2021